ArticleInternational journal of nanomedicine2026
Sialic Acid-Targeting Lectin-Conjugated Oxygen Nanosomes Alleviate Hypoxia and Promote Macrophage Activation in Pancreatic Cancer Cells.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is characterized by severe hypoxia and an immunosuppressive tumor microenvironment, which contribute to poor therapeutic responses. This study developed sialic acid-targeting Lectin-conjugated oxygen nanosomes (Lectin-ONs) to combine targeted oxygen delivery with hypoxia alleviation and macrophage activation. Methods: SNA- and MALII-conjugated oxygen nanosomes (SNA-ONs and MALII-ONs) were prepared and characterized for physicochemical properties, oxygen-loading and release behavior, stability, cytocompatibility, and cellular binding. Their effects on hypoxia and macrophage activation were evaluated in pancreatic cancer cell models and macrophage-pancreatic cancer cell co-culture using hypoxia-sensitive fluorescence and TNF-α secretion, respectively. Results: Lectin-ONs exhibited stable physicochemical properties, effective oxygen delivery, and cellular binding to pancreatic cancer cells, while reducing hypoxia-associated fluorescence under oxygen-limited conditions. Treatment with Lectin-ONs also increased TNF-α secretion in macrophage-pancreatic cancer cell co-culture, consistent with macrophage activation. Conclusion: Lectin-ONs integrate sialic acid-targeted delivery with oxygen-mediated hypoxia alleviation and were associated with increased macrophage TNF-α secretion in vitro. These findings support Lectin-ONs as a potential platform for modulating the hypoxic and immunosuppressive microenvironment of pancreatic cancer, although further mechanistic and in vivo validation is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.